Literature DB >> 15919304

Total leukocyte control for elective coronary bypass surgery does not improve short-term outcome.

Robert F Salamonsen1, James Anderson, Michael Anderson, Michael Bailey, Geoff Magrin, Franklin Rosenfeldt.   

Abstract

BACKGROUND: Despite early promise as a means of reducing the inflammatory response to surgery and subsequent organ damage, the evidence of the clinical value of leukocyte filtration remains equivocal.
METHODS: Three hundred patients presenting for routine coronary artery bypass surgery were randomized to a total leukocyte filtration group (filters in five different locations) and a control group with a standard 40-mum filter in the bypass return line only. Data on efficacy and safety of leukocyte filtration were collected by research and postoperative care staff who were blinded to the mode of filtration.
RESULTS: Leukofiltration achieved a transient fall in white cells immediately after surgery (p = 0.07) and a sustained fall in platelets, which was still significant on the second postoperative day (p = 0.0001). However, there were no significant differences in postoperative hospital stay, the primary outcome variable (p = 0.35), in ICU stay (p = 0.92), or mortality (p = 1.0). There were no differences in postoperative cardiac status including cardiac output (p = 0.16), inotrope (p = 0.93) or balloon pump (p = 0.48) requirement, or 24-hour troponin (p = 0.60). Similarly there were no differences in pulmonary or renal function (intubation time (p = 0.83), respiratory index (p = 0.19) rise in creatinine (p = 0.13) or hemofiltration (1.0)). Leukofitration was not associated with a statistically significant increase in bleeding or requirement for blood or blood products. It was associated with a decrease approaching significance (p = 0.1) in number and severity of postoperative wound infections. Three filters were blocked during use but were changed without incident or compromise to patient safety.
CONCLUSIONS: Leukocyte filtration is safe but not efficacious in improving short-term outcome.

Entities:  

Mesh:

Year:  2005        PMID: 15919304     DOI: 10.1016/j.athoracsur.2004.11.038

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  4 in total

Review 1.  Use of leukocyte-depleting filters during cardiac surgery with cardiopulmonary bypass: a review.

Authors:  Shalini Boodram; Ed Evans
Journal:  J Extra Corpor Technol       Date:  2008-03

Review 2.  Prevention of acute kidney injury and protection of renal function in the intensive care unit. Expert opinion of the Working Group for Nephrology, ESICM.

Authors:  Michael Joannidis; Wilfred Druml; Lui G Forni; A B Johan Groeneveld; Patrick Honore; Heleen M Oudemans-van Straaten; Claudio Ronco; Marie R C Schetz; Arend Jan Woittiez
Journal:  Intensive Care Med       Date:  2010-03       Impact factor: 17.440

Review 3.  Leukoreduction for the prevention of adverse reactions from allogeneic blood transfusion.

Authors:  Daniel Simancas-Racines; Dimelza Osorio; Arturo J Martí-Carvajal; Ingrid Arevalo-Rodriguez
Journal:  Cochrane Database Syst Rev       Date:  2015-12-03

4.  Is leukocytosis a predictor for recurrence of ischemic events after coronary artery bypass graft surgery? A cohort study.

Authors:  Farid Rashidi; Peiman Jamshidi; Marziah Kheiri; Shadi Ashrafizadeh; Amir Ashrafizadeh; Fatemeh Abdolalian; Fatemeh Mirzamohamadi
Journal:  ISRN Cardiol       Date:  2012-07-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.